COVID-19, SARS-CoV-2
Conditions
Brief summary
The purpose of this study is to learn more about the acute response to infection with and recovery from the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some people know this virus by the name coronavirus. It can cause the disease called COVID-19. The information gained from the study can be used to help develop better tests for SARS-CoV-2 infection and COVID-19 disease and may help in developing future vaccines, other prevention strategies, and treatments.
Detailed description
This is a prospective study of acute immune responses to SARSCoV-2 infection. The study will include 3 groups, as described in the table below. Groups are defined based on clinical status at enrollment, but for the purposes of data analysis, participants who experience disease progression can contribute data to other cohorts. Participants will complete six visits over 28 days followed by a health contact at Month 2 (one month after the last scheduled visit). Additional follow up visit(s) may be added over time in response to evolving information regarding SARS-CoV-2 infection and COVID-19. Study visits may include review of medical history; interviews/questionnaires; pregnancy tests (for participants assigned female sex at birth); blood draws; nasal swab, nasal wash, and saliva sample collection; and optional stool sample collection.
Interventions
OTHERSample collection
* blood, nasal swab, nasal wash, and saliva * optional stool swab
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19 Prevention Network
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 years or older. * Test result indicating presence of SARS-CoV-2 virus. Sites must have results from assays that are approved as FDA-emergency use authorized or as standard-of-care by other applicable regional governing bodies. For timing of testing, please see group specific criteria below. * Ability and willingness to provide informed consent. * Willingness to have clinical research staff come to place of residence or hospital if needed. * Willingness to be followed for the planned duration of the study. * Assessment of understanding: volunteer demonstrates understanding of this study. * Agreement to allow access to medical records. * Asymptomatic participants: * No current symptoms. * No symptoms consistent with COVID-19 within 2 weeks prior to positive test according to the clinical judgement of the investigating clinician. Symptoms include, but are not limited to, fever, headache, sore throat, cough, dyspnea, rhinorrhea, diarrhea, myalgias, chills, and anosmia. Please refer to https://www.cdc.gov/coronavirus/2019-ncov/symptomstesting/symptoms.html for the current list of symptoms consistent with COVID-19. * Positive SARS-CoV-2 RNA test or antigen test within six days prior to enrollment (target time) up to 10 days prior to enrollment (upper allowable window). * Symptomatic (non-hospitalized) participants: * Onset of mild symptoms consistent with COVID-19 within 6 days prior to enrollment (target time) up to 14 days prior to enrollment (upper allowable window). Symptoms of COVID-19 to be determined by the clinical judgement of the investigating clinician including-- but not limited to-- fever, headache, sore throat, cough, dyspnea, rhinorrhea, diarrhea myalgias, chills, and anosmia. Please refer to https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html for the current list of symptoms consistent with COVID-19. * Positive SARS-CoV-2 RNA test or antigen test within six days prior to enrollment (target time) up to 10 days prior to enrollment (upper allowable window). * Symptomatic (hospitalized) participants * Participant hospitalized for COVID-19 within 3 days prior to enrollment (note: there is no timeframe for either symptom onset or timing of SARS-CoV-2 PCR or antigen testing for hospitalized participants)
Exclusion criteria
* Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence or a volunteer's ability to give informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Functional profiling, including intracellular cytokine staining, of SARS-CoV-2-specific CD4+ and CD8+ T cells | Measured through day 28 | Measured by flow cytometry |
| Response rate of SARS-CoV-2-specific B cells in peripheral blood samples | Measured through day 14 | Characterized using fluorescently labeled recombinant proteins in combination with a flow cytometry phenotyping panel |
| Magnitude of SARS-CoV-2-specific B cells in peripheral blood samples | Measured through day 14 | Characterized using fluorescently labeled recombinant proteins in combination with a flow cytometry phenotyping panel |
| Phenotypic characterization of SARS-CoV-2-specific B cells in peripheral blood samples | Measured through day 14 | Characterized using fluorescently labeled recombinant proteins in combination with a flow cytometry phenotyping panel |
| Response rate of SARS-CoV-2-specific antibody binding in serum samples | Measured through day 28 | Measured by binding antibody multiplex assay (BAMA) |
| Response rate of SARS-CoV-2-specific neutralizing antibodies in serum samples | Measured through day 28 | Measured by neutralizing antibody assay (nAb) |
| Magnitude of SARS-CoV-2-specific antibody binding antibodies in serum samples | Measured through day 28 | Measured by binding antibody multiplex assay (BAMA) |
| Magnitude of SARS-CoV-2-specific neutralizing antibodies in serum samples | Measured through day 28 | Measured by neutralizing antibody assay (nAb) |
| Response rate of SARS-CoV-2-specific binding antibodies in nasal wash samples | Measured through day 28 | Measured by binding antibody multiplex assay (BAMA) |
| Magnitude of SARS-CoV-2-specific binding antibodies in nasal wash samples | Measured through day 28 | Measured by binding antibody multiplex assay (BAMA) |
| Frequency of leukocyte populations in peripheral blood | Measured through day 14 | Measured by flow cytometry |
| Transcriptional profiles of peripheral blood leukocytes | Measured through day 14 | Measured by gene expression analysis by RNA sequencing, real-time PCR, single-cell proteogenomic profiling |
| Concentration of serum cytokines and other soluble factors | Measured through day 28 | Measured by multiplexed protein detection assays and/or enzyme-linked immunosorbent assays (ELISA) |
| Response rate of SARS-CoV-2-specific CD4+ and CD8+ T cells | Measured through day 28 | Measured by flow cytometry |
| Magnitude of SARS-CoV-2-specific CD4+ and CD8+ T cells | Measured through day 28 | Measured by flow cytometry |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quantitation of viral RNA in nasal swabs | Measured through day 28 | Measured by extraction of nucleic acid for analysis of microorganism RNA or DNA by qPCR and/or amplicon- or metagenomics-sequencing methods and subsequent gene and taxa-level bioinformatics analyses |
Countries
Argentina, Botswana, Brazil, Malawi, Mexico, Peru, South Africa, Tanzania, United States, Zambia, Zimbabwe
Outcome results
None listed